Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Life Sciences Vows To Maximize Post-Brexit Opportunities

Executive Summary

The UK is “open for business” as far as the life-sciences sector is concerned, and those with ministerial and departmental oversight are promising to work with the realities – still largely unknown – that the country's exit from the EU will bring forth. Such was the tone of UK Office for Life Sciences’ director Nicole Mather, speaking to health-care industry delegates Sept. 15 in London.

You may also be interested in...



Medtech Worried After UK HTA Body Moots Pharma Guidance Fees

The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.

UK Accelerated Access Proposals Due Out Soon

One aim of the soon-to-be-published proposals is to make the health environment in the UK more innovation-friendly, in particular for medtech and digital health products. The final report on the government’s Accelerated Access Review should be out by the end of the month.

Q&A: What's Next For UK Regs? ABHI's Phil Brown Discusses Post-Brexit Industry Strategizing

How should the UK medtech regulatory landscape look once the country separates from the EU? Phil Brown of the Association of British Healthcare Industries is helping to spearhead the effort to shape industry’s policy position on the matter. He spoke to Medtech Insight about options on the table and some potential implications.

Topics

Related Companies

UsernamePublicRestriction

Register

MT103835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel